If you have been reading about storage stability and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
== Discovery == An in silico search for potential small open-reading-frames (sORFs) within 16S ribosomal RNA-encoding short peptides (20–40 amino acids) was conducted in the Pinchas Cohen lab at University of Southern California. Six sequences encoding 20–38 amino-acid-long peptides were identified, which were named SHLP 1–6. The endogenous SHLPs were detected by immunoblots and their transcripts were validated by both qPCR and northern blot.
== Origins of pathology == Early understanding of the origins of diseases constitutes the earliest application of the scientific method to the field of medicine, a development which occurred in the Middle East during the Islamic Golden Age and in Western Europe during the Italian Renaissance. The Greek physician Hippocrates, the founder of scientific medicine, was the first to deal with the anatomy and the pathology of human spine. Galen developed an interest in anatomy from his studies of Herophilus and Erasistratus. The concept of studying disease through the methodical dissection and examination of diseased bodies, organs, and tissues may seem obvious today, but there are few if any recorded examples of true autopsies performed prior to the second millennium. Though the pathology of contagion was understood by Muslim physicians since the time of Avicenna (980–1037) who described it in The Canon of Medicine (c. 1020), the first physician known to have made postmortem dissections was the Arabian physician Avenzoar (1091–1161) who proved that the skin disease scabies was caused by a parasite, followed by Ibn al-Nafis (b. 1213) who used dissection to discover pulmonary circulation in 1242. In the 15th century, anatomic dissection was repeatedly used by the Italian physician Antonio Benivieni (1443–1502) to determine cause of death. Antonio Benivieni is also credited with having introduced necropsy to the medical field. Perhaps the most famous early gross pathologist was Giovanni Morgagni (1682–1771).
==== Toxicology in aquatic environments ==== The most environmentally relevant species of these nanoparticles are silver chloride within marine ecosystems and organic thiols within terrestrial ecosystems. Once Ag0 enters the environment, it is oxidized to Ag+. Of the potential species formed in seawater, such as Ag2S and Ag2CO3, AgCl is the most thermodynamically favored due to its stability, solubility, and the abundance of Cl− in seawater. Research has shown that partially oxidized nanoparticles may be more toxic than those that are freshly prepared. It was also found that Ag dissolutes more in solution when the pH is low and bleaching has occurred. This effect, coupled with ocean acidification and increasing coral reef bleaching events, leads to a compounding effect of Ag accumulation in the global marine ecosystem. These free formed Ag+ ions can accumulate and block the regulation of Na+ and Cl− ion exchange within the gills of fish, leading to blood acidosis which is fatal if left unchecked. Additionally, fish can accumulate Ag through their diet. Phytoplankton, which form the base level of aquatic food chains, can absorb and collect silver from their surroundings. As fish eat phytoplankton, the silver accumulates within their circulatory system, which has been shown to negatively impact embryonic fish, causing spinal cord deformities and cardiac arrhythmia. The other class of organisms heavily affected by silver nanoparticles is bivalves.
HCF diet A high-carbohydrate, high-fiber diet. Hemochromatosis A condition in which excess iron levels are deposited in body tissues, damaging them. Characteristically, it causes diabetes among its other effects. It can be caused too much iron intake (the normal body conserves iron very well, and has few routes for discarded excess iron). In an inherited form, it is the most common genetic diseases in those of Northern European ancestry. It is less common in other populations. See: Bronze diabetes. Hemodialysis A mechanical method of cleaning the blood for people who have kidney disease. See also: Dialysis. Hemoglobin A1C (HbA1c) Hemoglobin is the substance in red blood cells that carries oxygen to the cells. Hemoglobin reacts with blood glucose in various ways; the HbA1c sub-type reacts irreversibly. Since blood cells live about 90 days or so, the amount of HbA1c present at any time is a record of how much glucose has been in the blood during that period. It is, therefore, a record of the average blood glucose level over that period, though it is biased toward more recent conditions during that period. Heredity inheritance of various traits. One's heredity is the "sum" of one's genes, and their expression, passed on by one's parents. An additional, and poorly understood, source of inherited traits is exogenetic inheritance in which alterations to genetic material during life (e.g., from chemical exposures) changes the expression of genes which are passed to offspring. High The state of having high blood sugar.
Sources: en.wikipedia.org
== Mechanism of action == Pioglitazone selectively stimulates the nuclear receptor peroxisome proliferator-activated receptor gamma (PPAR-γ) and to a lesser extent PPAR-α. It modulates the transcription of the genes involved in the control of glucose and lipid metabolism in the muscle, adipose tissue, and the liver. As a result, pioglitazone reduces insulin resistance in the liver and peripheral tissues, decreases gluconeogenesis in the liver, and reduces quantity of glucose and glycated hemoglobin in the bloodstream. Since 2004, pioglitazone and other active TZDs have been shown to bind to the outer mitochondrial membrane protein mitoNEET with affinity comparable to that of pioglitazone for PPARγ. Leriglitazone is a metabolite.
== Narcoterrorism == An unwanted by-product of Bolivia's cocaine industry was the importation of Colombian-style drug violence. In the late 1980s, Colombia's Medellín Cartel reportedly wielded considerable power in Bolivia, setting prices for coca paste and cocaine and terrorizing the drug underworld with hired assassins. Furthermore, drug barons, organized into families, had established their own fiefdoms in Cochabamba, Beni, and Santa Cruz departments, using bribes and assassinations to destroy local authority. In September 1986, three members of a Bolivian scientific team were slain in the Huanchaca National Park in Santa Cruz Department shortly after their aircraft landed beside a clandestine coca-paste factory. The murders led to the discovery of the country's largest cocaine-processing installation, as well as evidence of an extensive international drug-trafficking organization consisting mostly of Colombians and Brazilians. President Paz Estenssoro fired the Bolivian police commander and deputy commander as a result of their alleged involvement. In a related action, suspected traffickers in Santa Cruz murdered an opposition deputy who was a member of the congressional commission that investigated the Huanchaca case. In the late 1980s, there were several incidents of narcoterrorism against the United States presence, the judiciary, and antidrug agents. For example, the so-called Alejo Calatayu terrorist command claimed responsibility for a May 1987 bomb attack against the Cochabamba home of a DEA agent.
7759 University Drive 7777 University Drive 7798 Discovery Drive Anderson Building Barrett Building, home to the University of Cincinnati Cancer Center Blood Cancer Healing Center Bridgeway Pointe Clifton Physicians Office Building Dental Center East Building Elizabeth Place Florence Building Holmes Building Hoxworth Center Liberty Township Building Lindner Center of HOPE Mason Building Midtown Building Milford Building Montgomery Building North Building Proton Therapy Center Radiotherapy Ridgeway Tower Rookwood Tower Sleep Medicine Center South Building Surgical Center Timothy Freeman, MD, Center for Developmental Disabilities Trenton Building Tri-County Building University of Cincinnati Gardner Neuroscience Institute UC Medical Center UC Medical Center Emergency Department Varsity Village Imaging Center West Building West Chester Hospital West Chester Hospital Emergency Center White Oak Building Wyoming Primary Care
Sources: en.wikipedia.org
=== Social learning theory === Albert Bandura's social learning theory proposes that individuals learn through personal experience and observing others. Behaviors are shaped by rewards, punishments, and modeling, with reinforced behaviors being more likely to be repeated. The theory also explains that aggression is learned through observing aggressive actions, as shown in studies where children copied violent behavior after watching it. Television plays a role in teaching and reinforcing societal norms, including how to interact with individuals who have psychiatric disorders.
Acid-fastness is a physical property of certain bacteria, protozoa, and eukaryotic cells, as well as some subcellular structures, referring to their resistance to decolorization by acids during laboratory staining procedures. Once stained as part of a sample, these organisms can resist the acid and/or ethanol-based decolorization procedures common in many staining protocols, hence the name acid-fast. Historically, acid-fast stains were thought to stain lipids of the cells based on the observed characteristics of cell staining under a wide range of conditions, although the results were limited by the tools available, however as early as 1959 there were observations of how nucleic acids were acid fast. Dyes such as carbol fuchsin and auramine O penetrate the cell and bind to DNA and RNA, producing characteristic red or yellow-green fluorescence, respectively. The property of “acid-fastness” therefore reflects the organism’s ability to retain these dyes after acid–alcohol decolorization, a feature determined mainly by the integrity and composition of the outer cell wall rather than by any specific lipid chemistry. The mechanisms of acid-fastness vary by species. In the genus Mycobacterium, the property has been traditionally attributed to the high mycolic acid content of the cell wall, which indeed contributes to dye retention and resistance to decolorization.
=== Chemiluminescence === This technology is based on the luminescence of specific compounds when they bind to explosive particles. Its sensitivity can reach the nanogram (ppb) level. It can be applied in non-electronic formats, such as sprays and test papers, as well as in electronic devices.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
Reversed-phase HPLC is used to assess purity, and mass spectrometry confirms molecular mass. Amino acid analysis can verify composition. These methods are standard for peptide characterization.